

PFA-100[®] Analyzer Bibliography

System Description

Kundu S, Heilmann E, Sio R, Garcia C, Davidson R, Ostgaard R: **Description of an in vitro platelet function analyzer –PFA-100[™]**. Sem Thromb Hemost 1995; 21(suppl. 2):106-112.

Kundu S, Heilmann E, Sio R, Garcia C, Ostgaard R: **Characterization of an in vitro platelet function analyzer -PFA-100[™]**. Clin Appl Thrombosis/Hemostasis 1996; 2:241-249.

Heilmann E, Kundu S, Sio R, Garcia C, Gomez R, Christie D: **Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100[™]**. Thromb Res 1997; 87:159-164.

Kottke-Marchant K, Powers JB, Brooks L, Kundu, S, Christie DJ. **The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer PFA-100[®]**. Clinical and Applied Thrombosis and Hemostasis 1999; 5(2):122-130.

Böck M, de Haan J, Beck K-H, Gutensohn K, Hertfelder H-J, Karger R, Heim MU, Beeser H, Weber D, Kretschmer V. **Standardization of the PFA-100[®] platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking and oral contraceptives**. British Journal of Haematology, 1999; 106: 898-904.

Sestito A, Sciahbasi A, Landolfi R, Maseri A, Lanza GA, Andreotti F. **A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age**. Cardiologia 1999;44(7):661-665.

Dalby M., Davidson S., Burman S., Davies S: **Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser**; Platelets 2000, 11, 320-324.

Routine Clinical Applications

Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ: **PFA-100®: A new method for assessment of platelet dysfunction.** Sem Thromb Hemost 1998; 24(2):195-202.

Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ: **Performance of the platelet function analyzer PFA-100 in testing abnormalities of primary haemostasis.** Blood Coagul Fibrinolysis 1999; 10(1):25-31.

Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti M: **Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion.** Thromb Res 1999; 96: 213-217.

Francis J., Francis D., Larson L., Helms E., Garcia M.: **Can the Platelet Function Analyzer (PFA®)-100 test substitute for the template bleeding time in routine clinical practice?** Platelets 1999; 10:132-136.

Ortel T, James A, Thames E, Moore K, Greenberg C. **Assessment of primary hemostasis by PFA-100® analysis in a tertiary care center.** Thromb Haemost 2000; 84(1): 93-97.

Kretschmer V, Weippert-Kretschmer M: **Determination and treatment of disorders of primary hemostasis: Experience with routine application of the in vitro bleeding test.** Hämostaseologie 1999; 19(4):168-175.

Kerenyi A, Schlamadinger A, Ajzner E, Szegedi I, Kiss C, Pap Z, Boda Z, Muszbek, L: **Comparison of the PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function.** Thromb Res 1999; 96(6):487-492.

Salat A, Kroess S, Felfernig-Boehm D, Felfernig M, Fleck T, Schmidt D, Pulaki S, Mueller MR: **Comparison of in vitro closure time (PFA-100) with whole blood electrical aggregometry and platelet surface antigen expression in healthy volunteers;** Thromb Res 2002; 105: 205-208.

Lepantalo A, Beer J, Siljander P, Syrjala M, Lassila R: **Variability in platelet responses to collagen – Comparison between whole blood perfusions, traditional platelet function test and PFA-100;** Thromb Res 2001; 103:123-133.

Brockmann M, Beythien C, Magens M, Wilckens V, Kuehnl P, Gutensohn K: **Platelet hemostasis capacity in smokers – In vitro function analyses with 3.2% citrated whole blood;** Thromb Res 2001; 104:333-342.

Aspirin

Marshall PW, Williams AJ, Dixon RM, Growcott JW, Warburton S, Armstrong J, Moores J: **A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers.** Br J Clin Pharmacol 1997; 44:151-155.

Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. **Monitoring of aspirin (ASA) pharmacodynamics with the Platelet Function Analyzer PFA-100®.** Thromb and Haemost 2000;83:316-321.

Feuring M, Haseroth K, Janson CP, Falkenstein E, Schmidt BM, Wehling M: **Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100).** Int J Clin Pharmacol Ther 1999; 37(12):584-588.

Gum P, Kottke-Marchant K, Poggio E, Gurm H, Welsh P, Brooks L, Sapp S, Topol E: **Profile and prevalence of aspirin resistance in patients with cardiovascular disease.** Am J Cardio 2001; 88: 230-235.

Jilma B, Fuchs I. **Detecting aspirin resistance with the platelet function analyzer (PFA-100).** Am J Cardiol 2001; 88:1348-1349.

Peters AJ, Borries M, Gradaus F, Jax TW, Schoebel FC, Strauer BE: **In vitro bleeding test with PFA-100 – Aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.** J Thromb Thrombolys 2001; 12: 263-272.

Roller RE, Dorr A, Ulrich S, Pilger E: **Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100.** Blood Coag Fibrinol 2002; 13:277-281.

Cardiology

Gries A; Bode C; Gross S; Peter K; Boehrer H; Martin E: **The effect of intravenously administered magnesium on platelet function in patients after cardiac surgery.** Anesthesia and Analgesia 1999; 88(6):1213-1219

Francis J: **Platelet dysfunction detected at high shear in patients with heart valve disease.** Platelets 2000; 11(3):133-136.

Fischetti D, Sciahbasi A, Leone A, Niccoli G, Schiavoni G, Trani C, Mazzari M, Andreotti F: **Ticlopidine and Aspirin fail to suppress the increased platelet aggregability that follows percutaneous coronary interventions:** J. of Thrombosis and Thrombolysis 2000; 10: 265-269.

Héazard N, Metz D, Nazeyrollas P, Droulle C, Elaerts J, Potron G, Nguyen P: **Use of the PFA-100™ apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents.** Thromb Haemost 2000; 83: 540-544.

Slaughter T, Sreeram G, Sharma A, El-Moalem H, east C, Greenberg C: **Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by PFA-100® platelet function analyzer;** Blood Coag. and Fibrinol. 2001; 12: 85-93.

Madan M, Berkowitz S, Christie D, Jennings L, Smit A, Sigmon, Glazer S, Tchong: **Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention;** Am. Heart J.2001; 141 (2):

Raman S, Silverman N: **Clinical utility of the platelet function analyzer (PFA-100) in cardiothoracic procedures involving extracorporeal circulation:** J Thorac Cardiovasc Surg 2001;198-191.

Golanski J, Golanski R, Chizynski K, Iwaszkiewicz A, Rozalski B, Wieclawska B, Boncler M, Watala C: **Platelet hyperreactivity after coronary artery bypass grafting: the possible relevance to glycoprotein polymorphisms. A preliminary report:** Platelets 2001; 12: 241-247.

[Madan M, Berkowitz S, Christie D, Smit AC, Sigmon K, Tchong J: **Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100;** Am. Heart J. 2002: 144 \(1\).](#)

[\(LINK TO PDF OF JOURNAL REPRINT\)](#)

Pediatrics/Ob/Gyn

Carcao MD, Blanchette VS, Dean JA, He L, Kern MA, Stain AM, Sparling CR, Stephens D, Ryan G, Freedman J, Rand ML: **The Platelet Function Analyzer (PFA-100®): A novel *in vitro* system for evaluation of primary haemostasis in children.** Br J Haematol 1998; 101:70-73.

Rand, ML, Carcao MD, Blanchette VS, Chir B.: **Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting.** Semin Thromb Hemost 1998; 24(6):523-529.

Knofler R, Weissbach G, Kuhlisch E.: **Platelet function test in childhood. Measuring aggregation and release reaction in whole blood.** Semin Thromb Hemost 1998; 24(6):513-521.

Israels S, Cheang T, McMillan-Ward, Cheang M: **Evaluation of primary hemostasis in neonates with a new *in vitro* platelet function analyzer:** J. Pediatr; 138: 116-119.

Suzuki S, Morishita S: **The relationship between the onset of the labor mechanisms and the hemostatic system.** Immunopharmacology 1999; 43(2-3):133-140.

Suzuki S, Morishita S. **Platelet Hemostatic Capacity (PHC) and Fibrinolytic inhibitors during pregnancy.** Semin Thromb Hemost 1998; 24(5):449-451.

Dean J, Blanchette V, Carcao M, Stain A, Sparling C, Siekmann J, Turecek P, Lillicrap D, Rand M: **von Willebrand disease in a pediatric-based population – comparison of typ1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay;** Thromb Haemost 2000, 84: 401-409.

Marietta M, Castelli I, Piccinni F, Neri I, Bertesi M, Facchinetti F, Torelli G. **The PFA-100 system for the assessment of platelet function in normotensive and hypertensive pregnancies:** Clin Lab Haem 2001; 23:131-134.

Vincelot A, Nathan N, Collet D, Mehaddi Y, Grandchamp P, Julia A. **Platelet function during pregnancy - An evaluation using the PFA-100 analyser:** Br J Anaesth 2001; 87: 890-893.

Lippi G, Manzato F, Franchini M, Brocco G, Florenziani G, Guidi G: **Establishment of reference values for the PFA-100 platelet function analyzer in pediatrics:** Clin Exp Med 2001; 1: 69-70

von Willebrand Disease Assessment

Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D: **Screening for von Willebrand Disease with a new analyzer using high shear stress: A study of 60 cases.** Blood 1998; 91:1325-1331.

Di Paola J; Federici AB; Mannucci PM; Canciani MT; Kritzik M; Kunicki TJ; Nugent D: **Low platelet alpha sub(2) beta sub(1) levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system.** Blood 1999; 93(11):3578-3582.

Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P. **Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.** Thromb Haemost 1999;82(1):35-39.

Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D. **Therapeutic monitoring of von Willebrand disease: Interest and limits of a platelet function analyser at high shear rates.** British Journal of Haematology 1999;106(3):777-783.

Favoloro EJ, Facey D, Henniker A. **Use of a novel platelet function analyzer (PFA-100™) with high sensitivity to disturbances in von Willebrand Factor to screen for von Willebrand's Disease and other disorders.** Am. J Hematol 1999;62:165-174.

Sadler J, Manucci P, Berntrop N, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Siravastava A: **Impact, diagnosis and treatment of von Willebrand disease.** Thromb Haemost 2000; 84: 160-174.

Veyradier A, Fressinaud E, Boyer-Neumann C, Trossaert M, Meyer D: **von Willebrand factor ristocetin cofactor activity correlates with the platelet function in a high shear stress system,** Thromb Haemost 2000, 84: 27-728.

Schlamadinger A, Kerenyi A, Muszbek L, Boda Z: **Comparison of the O'Brian filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease.** Thromb Haemost 2000; 84(1): 88-92

Favoloro E, Kershaw G, Bukuya M, Hertzberg M, Koutts J: **Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies;** Haemophilia 2001; 7: 180-189.

Frank RD, Kunz D, Wirtz DC: **Acquired von Willebrand disease-hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin and continuous factor concentrate infusion:** Am J Hematol 2002; 70:64-71.

Franchini M, Gandini G, Manzato F, Lippi G: **Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand disease;** Haematologica 2002; 6:270.

De Jonge E, Levi M, Bueller HR, Berends F, Kesecioglu J: **Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects;** Intensive Care Med 2001; 27:1825-1829.

Drugs / Agents

Hüttner I, Boldt J, Haisch G, Suttner, Kumle B, Schulz H: **Influence of different colloids on molecular markers of haemostasis and platelet function in patients undergoing major abdominal surgery**; British Journal of the British Journal of Anaesthesia 2000; 85(3), 417-423.

Hergovich N, Aigner M, Eichler H-G, Entlicher J, Drucker C, Jilma B: **Paroxetine decreases platelet serotonin storage and platelet function in human beings**; Clin Pharmacol Ther 2000;68:435-442.

D'Anglemont De Tassigny A, Idée JM, Corot C: **Comparative Effects of Ionic and Nonionic Iodinated Low-Osmolar Contrast Media on Platelet Function with the PFA-100™ (Platelet Function Analyzer)**: Invest. Radiol. 2001; 36:276-282.

Dalby MCD, Dew ar A, Davidson SJ, Burman JF, Davies SW. **Evaluation of angiographic contrast media and platelet function with impedance aggregometry and the PFA-100® "platelet function analyser"**. Platelets 1999;10:293-297.

De Meijer A, Vollaard H, De Metz M, Verbruggen B, Thomas C, Novakova I. **Meloxicam, 15 mg/day, spares platelet function in healthy volunteers**. Clin Pharmacol Ther 1999;66:425-430.

Dogne J, de Leval X, Neven P, Rolin S, Wauters J, David J, Delarge J, Massereel B: **Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function**. Prostaglandins Leukot Essent Fatty Acids 2000; 62(5):311-317.

Warot D, Berlin I, Aymard G, Ankri A, Fabry C, Besse B, Lechat P, Diquit B: **Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects**. Fundam Clin Pharmacol 2000, 14(3), 231-236.

Porter JM, Crow e B, Cahill M, Shorten GD: **The effects of ropivacaine hydrochloride on platelet function: an assessment using the platelet function analyser (PFA-100)**: Anaesthesia 2001, 56:15-18.

Dogne JM, Rolin S, de Leval X, Benoit P, Neven P, Delarge J, Kolh P, Damas J, David JL, Masereel B: **Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531**: Cardiovasc Drug Rev 2001; 19: 87-96.

De Rossi L, Horn N, Baumert J, Gutensohn K, Hutschenreuter G, Rossaint R. **Xenon does not affect human platelet function in vitro**: Anaesth Analg 2001; 93:635-640.

Huettner I, Boldt J, Haisch G, Suttner S, Kumle B, Piper S, Berchthold G: **Influence of different colloids on molecular markers of haemostasis and platelet function in patients undergoing major abdominal surgery**: Br J Anaesth 2000; 85:417-423.

Horn N, De Rossi L, Robitzsch T, Hecker K, Hutschenreuter G, Rossaint R. **Sevoflurane inhibits unstimulated and agonist-induced platelet antigen expression and platelet function in whole blood in vitro**: Anesthesio 2001; 95:1220-12235

Drugs / Agents

Van Kraaij DJW, Hovestad-Witterland A HI, de Metz M, Vollaard EJ: **A comparison of the effects of nabumetone and meloxicam, two COX-2 preferential nonsteroidal anti-inflammatory drugs, on platelet COX-1 activity and platelet function**; Br J Clin Pharmacol 2002; 53:644-647.

Francischetti IMB, Andersen JF, Ribeiro JMC: **Biochemical and functional characterization of recombinant Rhodnius prolixus platelet aggregation inhibitor 1 as a novel lipocalin with high affinity for ADP and other adenosine nucleotides**; Biochemistry 2002; 41:3810-3818.

De Jonge E, Levi M, Bueller HR, Berends F, Kesecioglu J: **Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects**; Intensive Care Med 2001; 27:1825-1829.

Emerging Applications

Escolar G, Cases A, Vinas M, Pino, M, Calls J, Cirera I, Ordinas A. **Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100™): Influence of hematocrit evaluation.** Haematologica 1999; 84(7):614-619.

Borzini P. **Platelet cryopreservation using second-messenger effectors and low-dose (2%) dimethyl sulfoxide. In vitro evaluation of post-thawing platelet activity with the platelet function analyzer;** Haematologica 2000, 85(8); 885-887.

Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V: **Influence of ABO blood groups on primary hemostasis;** Transfusion 2001; 41:56-60.

Lippi G, Franchini M, Brocco G, Manzanto F: **Influence of the ABO blood type on the platelet function analyzer PFA-100;** Thromb. Haemost. 2001; 85:369-370.

Borzini P, Lazzaro A, Mazzucco LTI: **Evaluation of the hemostatic function of stored platelet concentrates using the platelet function analyzer PFA-100™.** Haematologica 1999; 84(12):1104-1109.

Homoncik M, Blann A, Hollenstein U, Pernerstorfer T, Eichler H-G, Jilma B: **Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100;** British J. of Haemat. 2000;111:1250-1252.

Boehlen F, Michel M, Reber G, de Moerloose P: **Analysis of platelet function before and after thrombapheresis using the platelet function analyzer PFA-100;** Thromb. Res. 2001; 102: 49-52.

Feuring M, Gutfleisch A, Ganschow A, Richter E, Eichler H, Dempfle C, Tillmann A, Schultz A, Wehling M: **Impact of plasmapheresis on platelet hemostatic capacity in healthy blood donors detected by the platelet function analyzer PFA-100™;** Platelets 2001; 12: 236-240.

Boldt J, Huttner I, Suttner S, Kumle B, Piper S, Berchthold G: **Changes in haemostasis in patients undergoing major abdominal surgery – Is there a difference between elderly and younger patients?** Br J Anaesth 2001; 87: 435-440.

Jilma-Stohlawetz P, Hergovich N, Homoncik M, Dzirlo L, Horvath M, Janisiw M, Panzer S, Jilma B: **Impaired platelet function among platelet donors;** Thromb Haemost 2001; 86: 880-886

Jacoby R, Owings J, Holmes J, Battistella F, Gosselin R, Paglieroni T. **Platelet activation and function after trauma;** J Trauma 2001; 51:639-647.

Bozzo J, Tonda R, Hernandez MR, Alemany M, Galan AM, Ordinas A, Escolar G: **Comparison of the effects of human erythrocyte ghosts and intact erythrocytes on platelet interactions with subendothelium in flowing blood;** Biorheology 2001 38:429-437.

Westerbacka J, Yki-Jarvinen H, Turpeinen A, Rissanen A, Vehkavaara S, Syrjala M, Lassila R: **Inhibition of platelet-collagen interaction – An in vivo action of insulin abolished by insulin resistance in obesity;** Arterioscler Thromb Vasc Biol 2002; 22:167-172.

Veterinary Medicine

Keidel A, Mischke R: **Clinical evaluation of platelet function analyzer PFA-100 in dogs**. Berl Munch Tierarztl Wochenschr 1998; 111(11-12):452-6.

Nimmerfall K, Mischke R: **Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs**. Dtsch Tierarztl Wochenschr 1999; 106 (10):439-444.

Escudero C, Santos M, Buján J, Fuente M, Honduvilla NG, Banás E, San Román J, Tendillo FJ: **Optical aggregometry versus the PFA-100™: experimental studies in pigs treated with propofol**: Platelets 2001; 12, 133-137.

Callan MB, Giger U: **Assesment of a point-of-care instrument for identification of primary hemostatic disorders in dogs**. AJVR 2001; 62 (5): 652-658

Review articles

Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, Feigen LP, Lansky DM, Salyers AK: **Assessment of platelet function assays**. Am Heart J 1998; 135:170-178,

McKenzie M, Gurbel P, Levine D, Serebruany V: **Clinical utility of available methods for determining platelet function**. Cardiology 1999; 92(4): 240-247.

Favaloro E: **Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations**; Haemophilia 2001; 7: 170-179.

Favaloro E: **Laboratory assesment as a critical component of the appropriate and sub-classification of von Willebrand's disease**. Blood Review 1999; 13: 185-204.

Harrison P: **Progress in the assessment of platelet function**: British J. of Haematolog. 2000; 111:733-744.